BBI Life Sciences Corporation announced unaudited consolidated earnings results for the six months ended June 30, 2016. For the period, the company reported revenue of RMB 164,207,000 against RMB 131,780,000 a year ago. Operating profit was RMB 34,297,000 against RMB 26,051,000 a year ago. Profit before income tax was RMB 37,021,000 against RMB 26,461,000 a year ago. Total profit attributable to equity holders of the company was RMB 28,733,000 or RMB 0.053 per diluted share and RMB against RMB 21,283,000 or RMB 0.039 per diluted share a year ago. Net cash generated from operating activities was RMB 7,846,000 against RMB 2,272,000 a year ago. Purchase of property, plant and equipment was RMB 33,751,000 against RMB 20,982,000 a year ago. Purchase of intangible assets was RMB 18,000 against RMB 1,834,000 a year ago. The increase in revenue was contributed by the steady growth of the Four Business Segments.